Page last updated: 2024-09-03

ym 022 and Neuroendocrine Tumors

ym 022 has been researched along with Neuroendocrine Tumors in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Boyce, M; Burkitt, MD; Dodd, S; Duckworth, CA; Exarchou, K; Fang, Y; Hall, N; Howes, N; Lloyd, KA; Moore, AR; Oxvig, C; Papoutsopoulou, S; Parsons, BN; Pritchard, DM; Rainbow, L; Varro, A	1

Trials

1 trial(s) available for ym 022 and Neuroendocrine Tumors

Article	Year
Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors. Cellular and molecular gastroenterology and hepatology, 2020, Volume: 10, Issue:1 Topics: Animals; Benzodiazepines; Benzodiazepinones; Cell Line, Tumor; Disease Models, Animal; Gastric Mucosa; Gastrins; Gene Knockdown Techniques; Humans; Mice; Mice, Transgenic; Neuroendocrine Tumors; Organoids; Phenylurea Compounds; Pregnancy-Associated Plasma Protein-A; Primary Cell Culture; Receptor, Cholecystokinin B; Stomach Neoplasms; Treatment Outcome	2020

Article

Year

Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.

Cellular and molecular gastroenterology and hepatology, 2020, Volume: 10, Issue:1

Topics: Animals; Benzodiazepines; Benzodiazepinones; Cell Line, Tumor; Disease Models, Animal; Gastric Mucosa; Gastrins; Gene Knockdown Techniques; Humans; Mice; Mice, Transgenic; Neuroendocrine Tumors; Organoids; Phenylurea Compounds; Pregnancy-Associated Plasma Protein-A; Primary Cell Culture; Receptor, Cholecystokinin B; Stomach Neoplasms; Treatment Outcome

2020